4th Quarter Results 2013: 28 February 2014
1st Quarter Results 2014: 22 May 2014
2nd Quarter Results 2014: 21 August 2014
3rd Quarter Results 2014: 20 November 2014
Annual General Meeting: 29 April 2014
All dates are tentative and could be subject to change.
###
For further information, please contact:
Mike Booth | +1 646 410 1884 |
Communications & Corporate Affairs | ir@algeta.com |
Media enquiries: | |
Mark Swallow | +44 207 638 9571 |
Citigate Dewe Rogerson | mark.swallow@citigatedr.co.uk |
Knut Ekern | +47 22 04 82 00 |
Gambit Hill & Knowlton | knut.ekern@hkstrategies.com |
Kari Watson | +1 781 235 3060 |
MacDougall Biomedical Communications | kwatson@macbiocom.com |
Investor enquiries: | |
Tricia Truehart | +1 646 378 2953 |
The Trout Group | t truehart@troutgroup.com |
About Algeta
Algeta is a company focused on developing, manufacturing and marketing novel targeted therapies for patients with cancer. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
distributed by |